paramyxoviru
pneumoviru
famili
belong
order
mononegaviral
includ
addit
major
human
pathogen
famili
filovirus
rhabdovirus
characterist
order
lipidenvelop
virion
contain
neg
sens
nonseg
nn
rna
genom
genom
antigenom
rna
viral
nucleoproteinencapsid
result
format
ribonucleoprotein
rnp
complex
spread
respiratori
rout
paramyxo
pneumovirus
highli
contagi
caus
collect
major
morbid
mortal
worldwid
particular
pediatr
patient
older
adult
among
immun
compromis
instanc
paramyxovirus
repres
major
health
threat
transplant
patient
alon
infect
current
hematopoiet
stem
cell
transplant
recipi
approxim
patient
develop
sever
diseas
viral
spread
small
airway
coincid
increas
casefat
rate
infect
remain
restrict
upper
respiratori
tract
patient
viral
pneumonia
approv
vaccin
prophylaxi
antivir
therapeut
current
avail
protect
hpiv
infect
improv
diseas
manag
anoth
exampl
sever
unmitig
paramyxoviru
diseas
provid
niv
zoonot
member
famili
belong
henipaviru
genu
henipavirus
highli
pathogen
human
mani
anim
caus
system
infect
sever
neurolog
complic
past
two
decad
repeat
niv
outbreak
asian
region
origin
transfer
viru
natur
bat
host
domest
anim
result
casefat
rate
reach
continu
spillov
human
popul
must
expect
humantohuman
transmiss
respiratori
secret
urin
saliva
document
pneumovirus
rsv
infect
almost
children
two
year
age
respons
hospit
yearli
unit
state
alon
monoclon
antibodi
palivizumab
approv
immunoprophylaxi
rsv
infect
howev
use
restrict
highrisk
patient
due
highcost
need
prophylact
administr
given
health
medic
econom
burden
associ
paramyxo
pneumoviru
infect
major
current
unmet
clinic
need
exist
expedit
develop
novel
safe
effect
therapeut
improv
diseas
manag
outbreak
control
current
directact
therapeut
predominantli
focu
prevent
viral
entri
neutral
antibodi
nab
smallmolecul
target
envelop
glycoprotein
inhibit
viral
rnadepend
rna
polymeras
rdrp
complex
reflect
major
effort
identifi
costeffect
altern
highpric
passiv
immun
antirsv
nab
number
compound
enter
advanc
preclin
develop
clinic
test
recent
year
tabl
breakthrough
structur
function
character
viral
entri
machineri
polymeras
complex
past
decad
furthermor
creat
novel
opportun
structureinform
mechanist
character
ligand
optim
focu
pharmaceut
target
viral
entri
machineri
discuss
follow
main
stage
pneumo
paramyxoviru
f
proteinmedi
membran
fusion
examin
conform
rearrang
requir
membran
merger
structur
framework
viral
entri
process
overlaid
known
neutral
epitop
target
site
smallmolecul
entri
inhibitor
better
appreci
underli
mechan
inhibit
structur
basi
viral
resist
potenti
counteract
viral
escap
proactiv
ligand
engin
physiolog
oligom
paramyxoviru
attach
protein
homotetram
consist
dimerofdim
insert
viral
envelop
type
transmembran
protein
orient
nativ
attach
protein
tetram
consist
membranedist
globular
head
domain
membraneproxim
coiledcoil
stalk
figur
head
domain
paramyxoviru
attach
protein
type
assum
overal
sixblad
propel
fold
sialidas
howev
hn
protein
found
instanc
member
respiroviru
rubulaviru
genera
actual
neuraminidas
activ
paramyxovirus
hntype
attach
protein
use
sialic
acid
moieti
display
target
cell
plasma
membran
receptor
contrast
morbillivirus
mev
henipavirus
enter
cell
proteinac
receptor
case
mev
ephrintyp
receptor
case
niv
elimin
need
neuraminidas
catalyt
activ
sialidaselik
fold
head
domain
nevertheless
conserv
also
across
morbillivirus
henipavirus
indic
sialic
acidmedi
attach
target
cell
repres
entri
strategi
common
ancestr
paramyxoviru
pneumoviru
g
protein
lack
hemagglutin
neuraminidas
activ
structur
inform
limit
compar
avail
paramyxoviru
attach
protein
pneumoviru
g
conform
distinct
share
sialidaselik
fold
characterist
paramyxovirus
wherea
paramyxoviru
attach
protein
furthermor
essenti
virion
infect
recombin
rsv
lack
g
could
recov
propag
cell
cultur
indic
rsv
f
must
cell
attach
membran
fusion
activ
howev
rsv
g
act
import
virul
factor
rsv
recombin
apathogen
vivo
exact
mechanist
contribut
rsv
g
membran
fusion
unclear
function
interact
rsv
f
establish
experiment
examin
homo
heterotyp
f
g
protein
compar
attach
protein
overal
fold
f
protein
conserv
across
two
famili
f
protein
integr
membran
protein
type
topolog
synthes
bioinact
precursor
protein
requir
proteolyt
matur
physiolog
oligom
homotrim
trimer
assum
nativ
conform
gain
intracellular
transport
compet
accordingli
newli
synthes
f
trimer
endoplasm
reticulum
er
case
morbillivirus
er
also
site
subsequ
heterooligomer
attach
fusion
protein
complex
f
trimer
assum
initi
metast
prefus
fold
resembl
lollipoplik
shape
figur
consist
membraneproxim
coiledcoil
prefus
stalk
singl
globular
head
domain
stalk
head
domain
cooper
form
three
monom
stalk
connect
transmembran
domain
short
ctermin
cytosol
tail
anchor
transmembran
domain
lipid
envelop
add
stabil
prefus
conform
consequ
crystal
structur
prefus
niv
f
ectodomain
could
obtain
transmembran
domain
replac
solubl
trimer
domain
crystal
prefus
mev
rsv
f
requir
addit
disulfid
bond
andor
caviti
fill
mutat
stabil
solubl
ectodomain
paramyxo
pneumoviru
f
protein
proteolyt
matur
mediat
host
cell
furintyp
proteas
resid
golgi
apparatu
cleavag
gener
monom
larger
membraneembed
shorter
fragment
remain
coval
connect
intramonomer
disulfid
bond
newli
liber
nterminu
posit
begin
fusion
peptid
stretch
larg
hydrophob
amino
acid
function
membran
attack
group
insert
target
membran
fusion
process
directli
adjac
fusion
peptid
transmembran
domain
highli
conserv
amphipath
region
heptad
repeat
hr
pattern
hra
hrb
domain
respect
thermodynam
stabl
postfus
conform
f
trimer
assum
overal
coneshap
form
figur
f
character
larg
central
tripl
helix
coiledcoil
form
hra
domain
prefus
f
hra
helic
broken
distinct
structur
element
form
membranedist
section
prefus
f
head
shorter
hrb
domain
pack
groov
tripl
helix
result
thermodynam
highli
stabl
bundl
fusion
core
arrang
hradjac
transmembran
domain
fusion
peptid
consequ
viral
envelop
target
membran
direct
proxim
resid
lipid
bilay
trigger
pneumo
paramyxoviru
f
protein
membran
fusion
receptor
bindinginduc
phindepend
case
paramyxovirus
attach
protein
head
domain
assum
prereceptor
bound
headsdown
postreceptor
headsup
orient
rel
attach
protein
stalk
domain
truncat
attach
protein
lack
head
domain
engin
paramyxovirus
rubulaviru
morbilliviru
respiroviru
henipaviru
genu
attach
protein
stem
trigger
refold
homotyp
f
protein
indiscrimin
receptor
bind
indic
attach
protein
stalk
act
effector
domain
wherea
attach
protein
head
function
activ
regul
common
theme
fusion
trigger
receptor
bind
result
conform
rearrang
attach
protein
head
domain
move
headsdown
headsup
posit
case
rubula
respiroviru
hn
protein
chang
expos
f
interact
site
hn
stalk
result
heterooligomer
hn
tetram
f
trimer
trigger
f
refold
contrast
morbilliviru
envelop
protein
first
heterooligomer
host
cell
er
indic
headsdown
arrang
attach
protein
steric
mask
f
interact
site
stalk
domain
rather
receptor
bind
morbilliviru
h
protein
associ
subsequ
head
domain
rearrang
thought
initi
conform
chang
h
stalk
trigger
refold
preassoci
f
trimer
accord
safetycatch
model
f
refold
cascad
activ
either
trigger
attach
protein
case
pneumovirus
direct
f
interact
receptor
assembl
hra
tripl
helix
propel
fusion
peptid
toward
target
membran
result
linkag
fusion
donor
acceptor
lipid
envelop
f
protein
extend
prehairpin
conform
subsequ
concert
hairpin
format
sever
f
trimer
zipper
domain
local
introduc
extrem
neg
curvatur
away
cytoplasm
virion
lumen
respect
lipid
bilay
result
local
disarray
lipid
layer
approach
fusion
tip
facilit
membran
merger
thu
f
protein
mediat
fusion
pore
open
act
membran
bend
machin
thought
driven
predominantli
free
energi
releas
assembl
two
predomin
mechan
product
interfer
f
protein
function
synthet
antivir
emerg
latestag
inhibit
fusion
core
assembl
peptid
inhibitor
stabil
prefus
f
conform
smallmolecul
compound
synthet
antif
peptid
deriv
residu
homotyp
close
relat
hrb
domain
block
closur
competit
endogen
hrb
access
hra
tripl
helix
groov
consequ
peptid
act
late
f
refold
cascad
trap
trimer
prehairpin
conform
analog
mechan
action
propos
clinic
approv
directact
antivir
peptid
hiv
entri
inhibitor
fuzeon
although
efficaci
fuzeon
also
embodi
liabil
hrderiv
therapeut
peptid
drug
product
difficult
manufactur
result
high
treatment
cost
oral
bioavail
lack
virusderiv
peptid
immunogen
caus
sever
inject
site
reaction
reflect
limit
synthet
peptid
advanc
preclin
develop
clinic
trial
mostli
focus
smallmolecul
antivir
februari
eight
smallmolecul
rsv
entri
inhibitor
advanc
stage
clinic
test
tabl
common
characterist
drug
candid
includ
except
high
potenc
nanomolar
subnanomolar
rang
oral
bioavail
high
target
specif
low
genet
barrier
viral
resist
although
chemotyp
structur
distinct
advanc
rsv
entri
inhibitor
pharmacophor
solv
bind
overlap
druggabl
site
central
f
caviti
near
base
f
head
domain
figur
stabil
prefus
conform
trimer
lock
fusion
peptid
place
accordingli
escap
mutat
affect
residu
fusion
peptid
ie
line
bind
site
ie
resist
hotspot
locat
interfac
prefus
f
head
stalk
domain
ie
contribut
stabil
metast
prefus
conform
f
protein
consist
distinct
posit
resist
site
viral
escap
thought
reflect
distinct
principl
substitut
directli
line
target
site
alloster
affect
shape
reduc
bind
affin
ligand
without
alter
conform
stabil
prefus
f
secondli
mutat
f
headstalk
interfac
destabil
prefus
fold
narrow
window
opportun
product
interact
inhibitor
prefus
f
acceler
rate
f
refold
kineticsbas
secondari
escap
mechan
character
phenotyp
f
hyperfus
activ
two
factor
particular
exacerb
anticip
neg
impact
rapidli
emerg
resist
clinic
potenti
rsv
entri
inhibitor
firstli
sever
hot
spot
identifi
mediat
univers
escap
inhibit
advanc
rsv
entri
inhibitor
test
despit
structur
divers
differ
chemotyp
exist
panresist
site
suggest
may
challeng
proactiv
counteract
viral
escap
synthet
scaffold
optim
support
notion
largescal
highthroughput
drug
screen
use
recombin
rsv
strain
carri
signatur
panresist
mutat
return
hit
block
f
protein
activ
although
entri
inhibitor
typic
emerg
readili
often
pharmacodomin
antirsv
drug
screen
secondli
studi
mous
rsv
pathogenesi
model
demonstr
earli
signatur
panresist
mutat
mandatorili
coincid
viral
attenu
vivo
rais
substanti
concern
entri
inhibitorresist
rsv
may
emerg
rapidli
field
remain
pathogen
possibl
abl
spread
beyond
rsv
pneumo
paramyxoviru
entri
inhibitor
candid
subject
advanc
structur
character
target
dock
pose
none
progress
clinic
test
except
chemic
wellbehav
smallmolecul
mev
inhibitor
potent
block
mev
f
proteinmedi
membran
fusion
primari
resist
hot
spot
f
residu
locat
noncoval
interact
network
affix
base
prefus
f
head
domain
hrb
deriv
stalk
figur
resolut
intramolecular
interfac
demonstr
prerequisit
f
refold
drugresist
mev
f
hyperfusogen
illumin
conserv
role
microdomain
control
conform
stabil
prefus
f
protein
ultim
confirm
block
mev
entri
lock
f
prefus
conform
came
mev
doubl
mutant
carri
addit
substitut
defin
caviti
form
subunit
depend
dosedepend
stabil
maintain
intracellular
transportcompet
conform
display
cell
surfac
complex
effici
stimul
mev
h
upon
receptor
bind
underscor
compound
inde
preserv
fusioncompet
fold
f
mechanist
character
mode
action
confirm
highresolut
crystal
structur
prefus
mev
f
complex
inhibitor
posit
compound
base
central
f
caviti
direct
proxim
residu
despit
overal
similar
dock
pose
rsv
mev
f
inhibitor
former
physic
engag
residu
fusion
peptid
contrast
dock
distal
fusion
peptid
interact
exclus
residu
line
central
f
caviti
presum
reflect
familyspecif
differ
geometri
prefus
f
head
domain
pneumo
paramyxovirus
figur
structur
f
protein
complex
neutral
antibodi
solv
number
pneumo
paramyxoviru
famili
member
includ
rsv
figur
niv
distinct
antigen
site
identifi
rsv
f
figur
conformationdepend
site
locat
apex
prefus
f
domin
target
nab
site
ii
iv
present
pre
postfus
f
conform
site
iii
likewis
exist
f
conform
undergo
rearrang
secondari
structur
element
form
epitop
site
v
locat
site
iii
prefus
f
postfus
f
site
cryoem
structur
f
complex
nab
likewis
locat
bind
site
apex
prefus
f
trimer
establish
contact
residu
three
f
protom
underscor
membranedist
domain
f
protein
immuneaccess
two
niv
f
nab
complex
recent
report
locat
bind
site
apex
prefus
f
adjac
quaternari
epitop
respect
figur
bind
site
antibodi
conserv
hendra
viru
f
result
good
crossneutr
natur
druggabl
site
near
base
central
prefus
f
caviti
steric
access
antibodi
bind
pharmacodomin
site
highli
potent
small
molecul
entri
inhibitor
character
far
nevertheless
remark
sinc
map
nab
reveal
divers
set
altern
site
membranedist
region
f
head
engag
stabil
f
prefus
fold
current
lack
small
molecul
ligand
direct
antigen
site
presum
directli
reflect
fundament
differ
natur
bind
site
mode
target
engag
antibodi
small
molecul
drug
typic
proteinprotein
interfac
includ
antigenantibodi
flat
geometri
span
larg
intern
surfac
footprint
antibodi
approx
includ
numer
polar
hydrophob
interact
comparison
small
molecul
cover
protein
surfac
target
site
show
concav
ensur
favor
contact
multipl
site
ligand
although
therefor
challeng
recapitul
effect
nab
small
molecul
function
mimicri
achiev
hotspot
residu
protein
surfac
known
contribut
overproport
interact
howev
promis
superior
pharmacokinet
properti
small
molecul
drug
greater
flexibl
administr
differ
rout
superior
stabil
costeffect
revit
effort
replac
antibodi
confirm
therapeut
impact
small
molecul
mimic
antibodi
bind
function
proofofconcept
clinic
potenti
approach
come
instanc
attempt
small
moleculetarget
pathway
cancer
therapi
nab
epitopeinform
design
small
molecul
altern
broadli
neutral
antiinfluenza
viru
antibodi
direct
ha
stem
domain
given
dramat
expans
highresolut
structur
insight
product
nabf
protein
interact
recent
year
excit
see
whether
knowledg
equal
har
structureguid
develop
new
class
pneumo
paramyxoviru
entri
inhibitor
small
molecul
rsv
entri
inhibitor
enter
clinic
test
phase
far
five
advanc
efficaci
test
tabl
major
phase
ii
trial
employ
establish
human
challeng
model
rsv
infect
base
experiment
infect
adult
healthi
volunt
thu
provid
framework
assess
treatment
control
predefin
condit
primari
efficaci
end
point
model
typic
shed
viru
load
nasal
swab
sampl
secondari
end
point
includ
total
mucu
weight
produc
acut
infect
period
symptom
score
current
avail
trial
outcom
data
show
three
entri
inhibitor
candid
test
presatovir
reduc
viral
burden
shorten
diseas
durat
andor
allevi
secondari
clinic
sign
presatovir
subsequ
advanc
phase
iib
trial
hospit
patient
suffer
rsv
infect
lung
hematopoiet
stem
cell
transplant
recipi
treatment
overal
welltoler
minim
advers
effect
presatovir
disappoint
overal
much
larger
patient
group
confirm
rsv
infect
despit
encourag
origin
perform
human
challeng
model
compound
fail
significantli
reduc
viru
load
patient
group
test
moreov
presatovir
impact
durat
hospit
adult
patient
cohort
allevi
diseas
symptom
improv
lung
function
lung
transplant
recipi
lower
rate
respiratori
failur
reduc
overal
mortal
stem
cell
transplant
recipi
although
antivir
impact
presatovir
margin
trial
substitut
signatur
resist
microdomain
ie
fusion
peptid
residu
residu
residu
emerg
patient
treatment
group
absent
placebotr
subject
patient
resist
virus
emerg
experienc
smaller
reduct
viral
load
clinic
outcom
similar
subject
without
viral
escap
indic
resist
virus
replic
effici
vivo
caus
enhanc
diseas
clinic
data
thu
confirm
earlier
evid
provid
resist
test
rsv
anim
model
underscor
multipl
molecular
rout
acquir
robust
resist
current
entri
inhibitor
avail
resist
rsv
variant
remain
pathogen
vivo
disappoint
outcom
four
presatovir
phase
iib
clinic
trial
certainli
cast
major
doubt
clinic
potenti
current
pursu
advanc
f
protein
entri
inhibitor
especi
consid
overlap
bind
site
differ
chemotyp
similar
mechan
activ
exist
sever
panresist
hotspot
given
mechanist
similar
origin
encourag
perform
presatovir
human
rsv
challeng
model
littl
reason
assum
altern
entri
inhibitor
scaffold
success
test
challeng
model
may
fare
better
phase
iib
trial
highresolut
structur
model
entri
inhibitor
prefus
f
greatli
advanc
appreci
molecular
mechan
fusion
inhibit
yet
suggest
path
viral
panresist
could
counteract
proactiv
ligand
engin
despit
subnanomolar
potenc
cell
cultur
assay
initi
attract
drug
profil
properti
therapeut
target
base
prefus
f
protein
caviti
may
ultim
effect
approach
address
rsv
problem
altern
alloster
substrateanalog
inhibitor
rsv
polymeras
complex
identifi
likewis
show
promis
druglik
properti
potent
block
viru
replic
cell
cultur
vivo
ultim
therapeut
target
polymeras
may
fruit
two
main
reason
enzymat
function
viral
polymeras
complex
initi
rna
synthesi
rna
elong
mrna
cap
cap
methyl
must
perform
multipl
time
complet
individu
viral
replic
cycl
contrast
entri
opportun
interfer
ii
polymeras
blocker
suppress
synthesi
structur
virion
compon
directli
also
heighten
viru
suscept
innat
host
antivir
respons
sinc
prevent
express
viral
nonstructur
immunemodulatori
protein
essenti
viral
pathogenesi
ultim
combin
entri
inhibitor
mechanist
distinct
antivir
polymeras
inhibitor
may
power
strategi
howev
heighten
development
cost
associ
approach
affect
econom
viabil
entri
inhibitor
could
lose
impact
longterm
resist
rsv
transmit
effici
viral
strain
emerg
circul
carri
preexist
resist
mutat
